Non-Small Cell Lung Cancer Coverage from Every Angle

FDA Brief: Bemcentinib Combination Given Fast Track Status for STK11-Altered Advanced Lung Cancer

By: JNCCN 360 Staff
Posted: Friday, November 19, 2021

On November 9, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a first-in-class selective AXL inhibitor bemcentinib in combination with a PD-1/PD-L1 agent for non–small cell lung cancer (NSCLC). Specifically, the treatment is designed for patients with STK11-altered advanced or metastatic NSCLC without actionable mutations. Up to 20% of patients with NSCLC harbor STK11 mutations.

Preclinical mouse models had previously shown that bemcentinib was effective in systemic inhibition of AXL as well as expansion of tumor-associated T cells and restoration of therapeutic response to anti–PD-1 checkpoint inhibition. The FDA’s decision was also based on phase II clinical trial data results. Patients with advanced NSCLC who had STK11/LKB1 mutations were administered bemcentinb and pembrolizumab. Results showed the combination treatment achieved an objective clinical response or clinical benefit for the three patients so treated.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.